逃避(道德)
可药性
免疫系统
免疫抑制
生物
免疫学
癌症研究
病毒学
抗原
医学
免疫
疾病
抗体
后天抵抗
作者
Qiang Zhang,Yue Kong,Yinglin Long,Xue Li,Liang Wang,Zhanhao Luo,Xiaoya Yang,Yanchun Xie,Quanwei Yu,Jing Yu,Dayi Liang,Wenhao Yuan,Xiaomin Cheng,Yaqi Su,Kaisa Cui,Guobao Tian,Zhen He,Ping Lan
标识
DOI:10.1016/j.xcrm.2026.102837
摘要
Immune evasion remains a major challenge in colorectal cancer (CRC) treatment. Here, we identify that druggable β-catenin palmitoylation at cysteine 466 (C466) by ZDHHC5 acts as a competitive switch, displacing S-nitrosylation and coordinating an immunosuppressive program. The palmitoylated state stabilizes the β-catenin/TCF4 complex, which simultaneously upregulates SLC7A11 to suppress immunogenic ferroptosis, critical for CD8 + T cell priming, and PD-L1 to inhibit cytotoxic CD8 + T cells, thereby impairing both the initiation and effector phases of anti-tumor immunity. Clinically, ZDHHC5 expression predicts poor survival and resistance to anti-PD-L1 therapy. Silencing ZDHHC5 reduced tumor growth in patient-derived organoids and xenografts, while Zdhhc5 ablation in mice inhibited CRC progression by reversing immunogenic ferroptosis suppression and alleviating PD-L1-mediated T cell inhibition. Importantly, β-cat-oxazole, a first-in-class inhibitor, disrupts ZDHHC5-β-catenin binding, thereby restoring immunogenic ferroptosis and blocking PD-L1-mediated immunosuppression, ultimately suppressing tumor growth. Our findings establish targeting of this palmitoyl-switch as a precision strategy to overcome therapeutic resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI